Why the study?
Is urinary excretion of leukotriene E4 increased in patients with Kawasaki disease compared to healthy controls?
Is urinary excretion of leukotriene E4 increased in patients with Kawasaki disease compared to healthy controls?
Urinary LTE4 is significantly elevated in Kawasaki disease, suggesting cysteinyl leukotrienes play a role in its pathophysiology and highlighting a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Supports cysteinyl leukotriene involvement in Kawasaki disease; hypothesis-generating and requires prospective validation before clinical consideration.
Endogenous cysteinyl leukotriene synthesis was assessed in 10 patients with Kawasaki disease and 10 healthy controls by measuring excretion of leukotriene E4 (LTE4) in urine. LTE4 was increased more than fivefold in patients with Kawasaki disease compared with controls (median (range) 55.3 (31.8-120.6) v 10.2 (7.1-14.9) nmol/mol creatinine); this suggests that cysteinyl leukotrienes are involved in the pathophysiology of Kawasaki disease. Leukotriene synthetase inhibition or receptor antagonism may therefore offer a new potential therapeutic approach in children with this disease.
No takes yet. Share an insight, caveat, or question.
Mayatepek et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: